A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

Agustí, Àlvar; Teresa, Luis de; Backer, Wilfried De; Zvarich, Michael T.; Locantore, Nicholas; Barnes, Neil; Bourbeau, Jean; Crim, Courtney

doi:10.1183/09031936.00054213

Cited by 50 publications

(37 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many new treatments for COPD have been recently released or are about to be launched [11][12][13][14]. They include mostly new LABD, ICS and various combinations of these agents.…”

mentioning

confidence: 99%

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

et al. 2014

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) pharmacological treatment aims to reduce symptoms, represented mostly by dyspnoea and its impact on daily life, and future risk, i.e. lung function decline, mortality and exacerbations [1]. Inhaled therapies, including long-acting bronchodilators (LABD) and inhaled corticosteroids (ICS), are the main treatments recommended for COPD patients. LABD have been found not only to improve lung function, decrease dyspnoea, increase exercise tolerance and improve health status, but also to reduce the rate of exacerbations. In that respect, some studies suggested that long-acting antimuscarinic agents (LAMA) could be more effective than long-acting β 2 -agonists (LABA) [2]. In most countries, ICS are indicated only as part of fixed-dose combinations (FDC) with LABA and are used mostly to decrease the risk of exacerbations, which is associated with health status improvement [3]. Therefore, it appeared logical to restrict their use to patients at high risk of exacerbations. The long-term benefit of combining LAMA and FDC (triple therapy) is not strongly documented [4].

show abstract

“…Many new treatments for COPD have been recently released or are about to be launched [11][12][13][14]. They include mostly new LABD, ICS and various combinations of these agents.…”

mentioning

confidence: 99%

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, it should be noted that benefits over a twice-daily ICS/LABA comparator were not shown [67]. In view of the fact that mometasone is effective when it is administered once daily, a fixed dose combination of mometasone and indacaterol (QMF149) administered via the Breezhaler device (Novartis) is being evaluated in patients with COPD, but no clinical data have yet been published [41].…”

Section: Laba/ics Combinationmentioning

confidence: 99%

Long-acting bronchodilators in COPD: where are we now and where are we going?

Cazzola

Page

2014

Breathe

View full text Add to dashboard Cite

Educational aimsTo discuss fundamental questions relating to the use of bronchodilators that can lead to an optimisation of their utilisation.To describe new bronchodilators that have recently been approved in some countries or are currently undergoing clinical developmentSummaryBronchodilators are central to the treatment of chronic obstructive pulmonary disease (COPD) because they alleviate bronchial obstruction and airflow limitation, reduce hyperinflation, and improve emptying of the lung and exercise performance. For this reason, all guidelines highlight that inhaled bronchodilators are the mainstay of the current management of all stages of COPD.However, there are still fundamental questions regarding their use that require clarification to optimise utilisation of these drugs. It is crucial to address the following questions. Is it appropriate to treat all COPD patients with long-acting bronchodilators? Is it better to start treatment with a β2-agonist or with an anti-muscarinic agent in patients with stable mild/moderate COPD? Is it useful to use a bronchodilator with rapid onset of action? Is it preferable to administer a bronchodilator on a once- or twice-daily basis? Can a second bronchodilator can be introduced for patients with stable COPD (“dual” bronchodilator therapy), and if so when? Are inhaled corticosteroids (ICSs) really useful in COPD patients without chronic bronchitis, since long-lasting bronchodilators may prevent exacerbations even in the absence of an ICS in frequent exacerbators? Finally, is combined therapy really useful in non-frequent exacerbators?Due to the the central role of bronchodilators in the treatment of COPD, there is still considerable interest in finding novel classes of bronchodilator drugs. However, new classes of bronchodilators have proved difficult to develop because either new emerging targets are not really important and/or it is difficult to find substances capable of interacting with them. As a consequence, many research groups have sought to improve the existing classes of bronchodilators.

show abstract

“…Die neueste Entwicklung ist die Fluticasonfuorat (92 µg)/Vilanterol (22 µg)-Fixkombination im Ellipta®-Inhaler [17,22]. Das Besondere daran ist die tägliche Einmalgabe [23][24][25][26]. Sie war in Bezug auf die FEV 1 -Verbesserung der Zweimalgabe der alten Fluticason/Salmeterol-Fixkombination nicht überle-gen [24].…”

Section: Neue Ics/laba-fix-kombinationenunclassified

Frischer Wind für COPD-geplagte Lungen

Gillissen¹

2014

MMW - Fortschritte der Medizin

View full text Add to dashboard Cite

Die COPD ist eine chronische Lungenerkrankung, die progredient verläu und in Deutschland vor allem durch jahrzehntelanges Zigarettenrauchen ausgelöst wird. Entsprechend der Recherchen für das Weißbuch Lunge 2014 der Deutschen Lungensti ung und der Deutschen Gesellscha für Pneumologie liegt die Prävalenz der COPD weltweit zwischen 1,3% und 13,2%, wobei wir für Deutschland 7,7% annehmen [1, 2]. Für die Pharmakotherapie stehen kurz und lang wirksame bronchodilatative und antiin ammatorische Medikamente zur Verfügung [3]. Die Bronchodilatatoren können einzeln oder in Kombination gegeben werden, während die antiin ammatorischen Substanzen nur zusammen mit einem Bronchodilatator anzuwenden sind. Ziele der Pharmakotherapie sind die Verbesserung der Lebensqualität, Senkung der typischen Symptome (insbesondere der Dyspnoe, Husten und AusAktuell wird der COPD-Markt mit neuen Substanzen, neuen Fixkombinationen und neuen Inhalern förmlich überschwemmt. Selbst für Spezialisten ist es schwierig, die einzelnen Produkte anhand der Vor-und Nachteile voneinander abzugrenzen und zu entscheiden, welches Produkt für welchen Patienten am sinnvollsten ist. Der nach folgende Beitrag gruppiert die Marktneulinge entsprechend ihres Wirkprinzips und gibt jeweils eine kurze Bewertung ab.

show abstract

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

Cited by 50 publications

References 40 publications

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

Long-acting bronchodilators in COPD: where are we now and where are we going?

Frischer Wind für COPD-geplagte Lungen

Contact Info

Product

Resources

About